Comparative Pharmacology
Head-to-head clinical analysis: ANTEPAR versus VERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTEPAR versus VERMOX.
ANTEPAR vs VERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Binds to β-tubulin in parasitic cells, inhibiting microtubule polymerization, thereby impairing glucose uptake and causing energy depletion and parasite death.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
Mebendazole 100 mg orally twice daily for 3 days for pinworm, whipworm, hookworm, and roundworm infections. For pinworm, may repeat after 2 weeks. For hookworm and whipworm, may require longer courses.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
2-8 hours (terminal half-life, may be prolonged in hepatic impairment or obstruction)
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Fecal (90%) as unchanged drug and metabolites; renal (<10%)
Category C
Category C
Anthelmintic
Anthelmintic